All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Long-term survival outcomes in patients with AML who were alive and disease-free 2 years after allo-HSCT
Bookmark this article
|
Although most deaths following allo-HSCT occur in the first 2 years post transplantation, long-term survivors are still at risk of late complications.1 A large, multicenter, retrospective, EBMT registry-based study assessed long-term survival and prognostic factors of late relapse in adult patients with acute leukemia who were alive and disease-free at 2 years after allo-HSCT. This analysis included 9,027 patients with AML who underwent allo-HSCT between 2005 and 2012. Results were published in Hemasphere by Larue et al.1 |
| Key learnings |
| The 10-year probability for OS and LFS was 76.2% and 72.3%, respectively. |
| The cumulative RI and NRM at 10 years was 15.6% and 12.1%, respectively, and the probability of cGRFS at 10 years was 68.1%. |
| Patient- and disease-specific factors: Older age and adverse cytogenetic profiles were associated with worse survival outcomes. |
| Transplant-specific factors: PB grafts vs BM grafts, and female donor to male recipient transplantation were associated with inferior survival outcomes. The use of RIC vs MAC was associated with higher OS, LFS, and NRM, and the use of ATG was associated with higher OS and LFS, and lower NRM and cGvHD. |
| Relapses (42.7%) and cGvHD (17.0%) were the most common cause of late mortality. |
| These findings underscore the importance of optimizing pre-transplant strategies and the need for targeted interventions and surveillance strategies in long-term survivorship care to reduce late complications and improve survival outcomes. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; cGRFS, composite of chronic graft‐versus‐host disease‐free and relapse‐free survival; cGvHD, chronic graft-versus-host disease; EBMT, European Society for Blood and Marrow Transplantation; LFS, leukemia-free survival; MAC, myeloablative conditioning; NRM, non-relapse mortality; OS, overall survival; PB, peripheral blood; RI, relapse incidence; UD, unrelated donor.
- Larue M, Labopin M, Schroeder T, et al. Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia. Hemasphere. 2024;8(10):e70026. DOI: 10.1002/hem3.70026
Your opinion matters
28 votes - 49 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox